Country: Canada
Language: English
Source: Health Canada
CLOZAPINE
AA PHARMA INC
N05AH02
CLOZAPINE
25MG
TABLET
CLOZAPINE 25MG
ORAL
100/500
Prescription
ATYPICAL ANTIPSYCHOTICS
Active ingredient group (AIG) number: 0122583001; AHFS:
APPROVED
2003-08-07
_AA-CLOZAPINE (Clozapine Tablets)_ _ _ _ _ _Page 1 of 55 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr AA-CLOZAPINE Clozapine Tablets Tablets, 25 mg, 50 mg, 100 mg and 200 mg, oral USP Antipsychotic Agent AA PHARMA INC. 1165 Creditstone Road, Unit #1 Vaughan, Ontario L4K 4N7 Date of Initial Authorization: AUG 19, 2016 Date of Revision: APRIL 03, 2023 Submission Control Number: 269276 _AA-CLOZAPINE (Clozapine Tablets)_ _ _ _ _ _Page 2 of 55 _ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Skin 04/2023 7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics 04/2023 7 WARNINGS AND PRECAUTIONS, General, Anticholinergic Activity 04/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ................................................................................................ 2 TABLE OF CONTENTS .................................................................................................................. 2 1 INDICATIONS ........................................................................................................................... 4 1.1 Pediatrics ............................................................................................................................... 5 1.2 Geriatrics ............................................................................................................................... 5 2 CONTRAINDICATIONS .............................................................................................................. 5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ......................................................................... 6 4 DOSAGE AND ADMINISTRATION .............................................................................................. 6 4.1 Dosing Considerations ........................................................................................................... 6 4.2 Recommended Dose and Dosage Adjustment ....................................... Read the complete document